Clinical Trials Browser

Phase 1/2 × Unknown × Biliary Tract Neoplasms × Clear all

NCT06255262 2024-02-13

Durvalumab Combined With Surufatinib as Maintenance Therapy in Patients With Advanced Biliary Tract Cancer

Phase 1/2 Unknown

Gastrointestinal

Biliary Tract Neoplasms

NCT06074029 2024-02-08

Exploratory Study on the Therapeutic Effect Prediction Model of Advanced BTC Immunotherapy

Phase 1/2 Unknown

Gastrointestinal

Biliary Tract Neoplasms

NCT03475953 2023-03-03

REGOMUNE

Phase 1/2 Unknown

BreastEndocrineGastrointestinalGenitourinaryHead & NeckNETOther solid neoplasmSarcomaThoracic

Gastro-enteropancreatic neuroendocrine tumor, Turcot syndrome, Tertiary Lymphoid Structures, Mesothelioma, Malignant, Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Neoplasm Metastasis, Sarcoma, Stomach Neoplasms, Thyroid Neoplasms, Triple Negative Breast Neoplasms

NCT05742750 2023-02-24

A Phase Ib/II Clinical Study of Camrelizumab and Apatinib Plus GP in the Treatment of Advanced Biliary Tract Cancer

Phase 1/2 Unknown

Gastrointestinal

Biliary Tract Neoplasms

NCT05357196 2022-05-02

PT-112 (Phosplatin's Platinum) Combine With Gemcitabine Injection for Advanced Solid Tumors

Phase 1/2 Unknown

Gastrointestinal

Biliary Tract Neoplasms

NCT05327582 2022-04-14

An Open-label, Phase I/II Study of PLENA Regimen in Patients With Unresectable Pancreatic Cancer or BTC

Phase 1/2 Unknown

Gastrointestinal

Biliary Tract Neoplasms, Pancreatic Neoplasms

NCT04004234 2019-07-09

A Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic BTC

Phase 1/2 Unknown

Gastrointestinal

Biliary Tract Neoplasms, Neoplasm Metastasis

NCT03311789 2017-10-17

Study of PD-1 Inhibitor in Combination With Gemcitabine/Cisplatin for Advancer BTCs

Phase 1/2 Unknown

Gastrointestinal

Biliary Tract Neoplasms